# US 2010/0168188 A1 · Estrogen Receptor Modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168188 A1
- Document ID: US20100168188A1
- Status: Published application
- Kind: A1
- Application number: 11/992,879
- Filed: 2006-09-29
- Published: 2010-07-01
- Earliest claimed: 2005-10-05
- Assignees: Merck Sharp & Dohme Corp.
- Inventors: Mark L. Greenlee; Dongfang Meng; Dann L. Parker, JR.; Wanying Sun; Kenneth J. Wildonger; Robert R. Wilkening
- Web page: https://patentgrep.com/patent/US20100168188A1

## CPC

- C07D 249/16: condensed with carbocyclic rings or ring systems
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07D 231/54: condensed with carbocyclic rings or ring systems
- C07D 235/02: condensed with carbocyclic rings or ring systems
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, metastatic bone disease, Paget's disease, periodontal disease, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, inflammation, inflammatory bowel disease, sexual dysfunction, hypertension, retinal degeneration and cancer, in particular of the breast, uterus and prostate.

## Claims

### Claim 1

A compound of the formula:
wherein Y is N or CRe;
Z is N or CRC;
R1 is hydrogen, C1-6alkyl, C2-6alkenyl or C2-6alkynyl, wherein said alkyl, alkenyl and alkynyl groups are optionally substituted with ORc, SRc, NRbRc, C(═O)Rc, C(═O)CH2OH, bromo, 1-3 chloro, 1-5 fluoro or phenyl, wherein said phenyl group is optionally substituted with C1-4alkyl, OH or O(C1-4alkyl);
R2 is hydrogen, hydroxy, iodo, O(C═O)Rc, C(═O)Rc, CO2Rc, C1-6alkyl, C2-6alkenyl, or C2-6alkynyl, wherein said alkyl, alkenyl and alkynyl groups are optionally substituted with ORc, SRc, NRbRc, C(═O)Rc, C(═O)CH2OH, or phenyl, wherein said phenyl group is optionally substituted with C1-4alkyl, OH or O(C1-4alkyl);
or R1 and R2, when taken together with the carbon atom to which they are attached, form a carbonyl group;
or R1 and R2, when taken together with the carbon atom to which they are attached, form a C3-7 cycloalkyl or C3-7 heterocycloalkyl group, wherein said heterocycloalkyl group is optionally substituted with C1-4 alkyl, OH, O(C1-4 alkyl) or oxo;
or R1 and R2, when taken together, form a C1-6 alkylidene group, wherein said alkylidene group is optionally substituted with hydroxy, O(C1-4alkyl), N(C1-4alkyl)2, or phenyl, wherein said phenyl group is optionally substituted with 1-3 substituents independently selected from the group consisting of C1-4alkyl, OH, O(C1-4alkyl), NH2, NH(C1-4alkyl), NH(C1-4alkyl)2, halo, CN, NO2, CO2H, CO2(C1-4alkyl), C(O)H and C(O)(C1-4alkyl);
R3 is hydrogen, fluoro, chloro, bromo, iodo, cyano, nitro, NRaRc, ORa, S(O)Ra, SO2Ra, SRa, C(═O)Ra, CO2Rc, CONRaRc, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, C3-7cycloalkyl, 4-7 membered heterocycloalkyl, cycloalkylalkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, aryl and heteroaryl groups are optionally substituted with 1, 2 or 3 groups independently selected from the group consisting of fluoro, chloro, bromo, iodo, cyano, ORa, NRaRc, O(C═O)Ra, O(C═O)NRaRc, NRa(C═O)Rc, NRa(C═O)ORc, C(═O)Ra, CO2Ra, CONRaRc, CSNRaRc, SRa, S(O)Ra, SO2Ra, SO2NRaRc, LRd, and MLRd;
R4 is hydrogen, hydroxy, amino, methyl, CF3, fluoro, chloro or bromo;
R5 is hydrogen, hydroxy, amino, methyl, CF3, fluoro, chloro or bromo;
R6 is hydrogen, (C═O)Ra, (C═O)ORa or SO2Ra;
R7 is hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, fluoro, chloro, bromo, cyano, hydroxy, O(C1-6 alkyl), azido, amino, NH(C1-4alkyl) or N(C1-4alkyl)2;
R8 is hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, fluoro, chloro, bromo, cyano, hydroxy, O(C1-6 alkyl), azido, amino, NH(C1-4alkyl) or N(C1-4alkyl)2;
or R7 and R8, when taken together with the carbon atom to which they are attached, form a 3-5 membered cycloalkyl ring;
or R7 and R8, when taken together with the carbon atom to which they are attached, form a carbonyl group;
or R7 and R8, when taken together, form a C1-6alkylidene group, wherein said alkylidene group is optionally substituted with cyano, C(═O)H, C(═O)(C1-4alkyl) or C(═O)OC1-4alkyl;
R9 is hydrogen, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, C3-6cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl groups are optionally substituted with bromo, iodo, ORb, SRb, C(═O)Rb, 1-3 chloro or 1-5 fluoro;
or R9 and R1, when taken together with the three intervening carbon atoms to which they are attached, form a 5-6 membered cycloalkyl or cycloalkenyl ring wherein said cycloalkyl or cycloalkenyl ring is optionally substituted with 1-3 groups independently selected from the group consisting of oxo, hydroxy, fluoro, chloro, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkylidenyl, C3-6cycloalkyl, cycloalkylalkyl, phenyl and phenylalkyl, wherein said alkyl, alkenyl, alkynyl, alkylidenyl, cycloalkyl, cycloalkylalkyl, phenyl, and phenylalkyl groups are optionally substituted with a group selected from chloro, bromo, iodo, ORb, SRb, C1-3alkyl, C(═O)Rb or 1-5 fluoro;
or R9 and R8, when taken together with the two intervening carbon atoms to which they are attached, form a cyclopropyl ring which is optionally substituted with 1 or 2 groups independently selected from the group consisting of C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, cycloalkylalkyl, phenyl and phenylalkyl, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, phenyl and phenylalkyl groups are optionally substituted with chloro, bromo, iodo, ORb, SRb, C1-3alkyl, C(═O)Rb or 1-5 fluoro;
R10 is hydrogen, C1-10alkyl or C2-10alkenyl;
R11 is hydrogen or ORa;
Ra is hydrogen, C1-10alkyl or phenyl, wherein said alkyl group is optionally substituted with hydroxy, amino, O(C1-4alkyl), NH(C1-4alkyl), N(C1-4alkyl)2, phenyl, or 1-5 fluoro, and wherein said phenyl groups are optionally substituted with 1-3 substituents independently selected from the group consisting of C1-4alkyl, OH, O(C1-4alkyl), NH2, NH(C1-4alkyl), NH(C1-4alkyl)2, halo, CN, NO2, CO2H, CO2(C1-4alkyl), C(O)H and C(O)(C1-4alkyl);
Rb is hydrogen, C1-10alkyl, benzyl or phenyl, wherein said phenyl group is optionally substituted with 1-3 substituents independently selected from the group consisting of C1-4alkyl, OH, O(C1-4alkyl), NH2, NH(C1-4alkyl), NH(C1-4alkyl)2, halo, CN, NO2, CO2H, CO2(C1-4alkyl), C(O)H and C(O)(C1-4alkyl);
Rc is hydrogen, C1-10alkyl or phenyl, wherein said phenyl group is optionally substituted with 1-3 substituents independently selected from the group consisting of C1-4alkyl, OH, O(C1-4alkyl), NH2, NH(C1-4alkyl), NH(C1-4alkyl)2, halo, CN, NO2, CO2H, CO2(C1-4alkyl), C(O)H and C(O)(C1-4alkyl);
or Ra and Rc, whether or not on the same atom, can be taken together with any attached and intervening atoms to form a 4-7 membered ring;
Rd is NRbRc, ORa, CO2Ra, O(C═O)Ra, CN, NRc(C═O)Rb, CONRaRc, SO2NRaRc, or a 4-7 membered N-heterocycloalkyl ring that is optionally interrupted by O, S, NRc, or C═O;
Re is hydrogen, C1-6alkyl, C2-6alkenyl, CF3, halo, O(C1-4alkyl), NH2, NH(C1-4alkyl) or N(C1-4alkyl)2;
Rf is hydrogen, C1-6alkyl, C2-6alkenyl, CF3, halo, O(C1-4alkyl), NO2, NH2, NH(C1-4alkyl) or N(C1-4alkyl)2;
L is CRbRc, C2-6 alkylene or C2-6 alkenylene, wherein said alkylene and alkenylene groups are optionally interrupted by O, S or NRc;
M is O, S, NRc, C═O, O(C═O), (C═O)O, NRc(C═O) or (C═O)NRc;
or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 2 (depends on 1)

The compound according to claim 1 wherein
R1 is hydrogen;
R2 is hydrogen;
R4 is hydrogen;
R5 is hydrogen;
R6 is hydrogen;
R9 is hydrogen, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, C3-6cycloalkyl, aryl or heteroaryl, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, aryl and heteroaryl groups are optionally substituted with bromo, iodo, ORb, SRb, C(═O)Rb, 1-3 chloro, or 1-5 fluoro;
or R9 and R1, when taken together with the three intervening carbon atoms to which they are attached, form a 5-6 membered cycloalkyl ring which is optionally substituted with 1-3 groups independently selected from oxo, hydroxy, fluoro, chloro, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkylidenyl, C3-6cycloalkyl, cycloalkylalkyl, phenyl, or phenylalkyl, wherein said alkyl, alkenyl, alkynyl, alkylidenyl, cycloalkyl, cycloalkylalkyl, phenyl, and phenylalkyl groups are optionally substituted with a group selected from chloro, bromo, iodo, ORb, SRb, C1-3alkyl, C(═O)Rb or 1-5 fluoro;
R10 is hydrogen;
or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 3 (depends on 2)

The compound according to claim 2 wherein
R3 is hydrogen, fluoro, chloro, bromo, iodo, cyano, C2-10alkenyl, C2-10alkynyl, C3-7cycloalkyl, 4-7 membered heterocycloalkyl, aryl or heteroaryl, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, aryl and heteroaryl groups are optionally substituted with 1, 2 or 3 groups independently selected from the group consisting of fluoro, chloro, bromo, iodo, cyano, ORa, NRaRc, O(C═O)Ra, O(C═O)NRaRc, NRa(C═O)Rc, NRa(C═O)ORc, C(═O)Ra, CO2Ra, CONRaRc, CSNRaRcC, SRa, S(O)Ra, SO2Ra, SO2NRaRe, LRd and MLRd;
R7 is hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, fluoro, chloro or bromo;
R8 is hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, fluoro, chloro or bromo;
or R7 and R8, when taken together with the carbon atom to which they are attached, form a carbonyl group;
or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 4 (depends on 3)

The compound according to claim 3 wherein
Ra is hydrogen or C1-6alkyl;
Rb is hydrogen;
Rc is hydrogen;
Re is hydrogen;
Rf is hydrogen;
or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 5 (depends on 4)

The compound according to claim 4 wherein
Y is N;
R11 is hydrogen, OH or OCH3;
R9 and R1 are taken together with the three intervening carbon atoms to which they are attached to form a 5-6 membered cycloalkyl ring which is optionally substituted with 1-3 groups independently selected from oxo, hydroxy, fluoro, chloro, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkylidenyl, C3-6cycloalkyl, cycloalkylalkyl, phenyl or phenylalkyl, wherein said alkyl, alkenyl, alkynyl, alkylidenyl, cycloalkyl, cycloalkylalkyl, phenyl and phenylalkyl groups are optionally substituted with a group selected from chloro, bromo, iodo, ORb, SRb, C1-3alkyl, C(═O)Rb or 1-5 fluoro;
or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 6 (depends on 1)

A compound according to claim 1 which is
(7R,8R,10aS)-6-chloro-3,7,8,9,10,11-hexahydro-8,10a-methanoazuleno-[2,1-e]indazol-7-ol;
(7R,8R,10aS)-6-(trifluoromethyl)-3,7,8,9,10,11-hexahydro-8,10a-methanoazuleno[2,1-e]indazol-7-ol;
(7R,8R,10aS)-6-chloro-7-methoxy-3,7,8,9,10,11-hexahydro-8,10a-methanoazuleno[2,1-e]indazole;
9a-ethyl-6-methyl-3,7,8,9,9a,10-hexahydroindeno[2,1-e]indazole;
(7R,8R,10aS)-6-(trifluoromethyl)-3,7,8,9,10,11-hexahydro-8,10a-methanocyclohepta[1,2]indeno[4,5-d][1,2,3]triazol-7-ol;
(7R,8R,10aS)-6-(trifluoromethyl)-3,7,8,9,10,11-hexahydro-8,10a-methanocyclohepta[1,2]indeno[4,5-d]imidazol-7-ol;
9a-ethyl-6-(trifluoromethyl)-3,7,8,9,9a,10-hexahydroindeno[2,1-e]indazole;
(9aS)-6-bromo-9a-(3-methylphenyl)-3,7,8,9,9a,10-hexahydroindeno[2,1-e]indazole;
(9aR)-6-chloro-9a-(5-chloro-2-furyl)-3,7,8,9,9a,10-hexahydroindeno[2,1-e]indazole;
(7R,8R,10aS)-6-bromo-3,7,8,9,10,11-hexahydro-8,10a-methanoazuleno[2,1-e]indazol-7-ol;
(7S,8R,10aS)-6-(trifluoromethyl)-3,7,8,9,10,11-hexahydro-8,10a-methanoazuleno[2,1-e]indazol-7-ol;
(7R,8R,10aR)-7-hydroxy-6-(trifluoromethyl)-7,8,9,10-tetrahydro-8,10a-methanoazuleno[2,1-e]indazol-11(3H)-one;
(7R,8R,10aR,11R)-11-fluoro-6-(trifluoromethyl)-3,7,8,9,10,11-hexahydro-8,10a-methanoazuleno[2,1-e]indazol-7-ol;
(7R,8R,9S,10aS)-9-fluoro-6-(trifluoromethyl)-3,7,8,9,10,11-hexahydro-8,10a-methanoazuleno[2,1-e]indazol-7-ol;
(7R,8R,10R,10aS)-10-methyl-6-(trifluoromethyl)-3,7,8,9,10,11-hexahydro-8,10a-methanoazuleno[2,1-e]indazol-7-ol;
(7R,8R,10aS)-6-(2-furyl)-3,7,8,9,10,11-hexahydro-8,10a-methanoazuleno[2,1-e]indazol-7-ol;
(7R,8R,10aS)-7-methoxy-6-(trifluoromethyl)-3,7,8,9,10,11-hexahydro-8,10a-methanoazuleno[2,1-e]indazole;
(9aS)-6-ethyl-9a-(4-fluorophenyl)-3,7,8,9,9a,10-hexahydrofluoreno[1,2-d][1,2,3]triazol-7-ol;
(9aS)-6-bromo-9a-(4-fluorophenyl)-3,7,8,9,9a,10-hexahydrofluoreno[1,2-d][1,2,3]triazole;
(7R,8R,10aS)-6-chloro-3,7,8,9,10,11-hexahydro-8,10a-methanocyclohepta[1,2]indeno[4,5-d][1,2,3]triazol-7-ol;
or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 7 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

### Claim 8 (depends on 1)

The use of a compound of claim 1 for the manufacture of a medicament useful for the treatment of: bone loss, bone fractures, osteoporosis, metastatic bone disease, Paget's disease, periodontal disease, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, anxiety, depression, perimenopausal depression, post-partum depression, premenstrual syndrome, manic depression, anxiety, dementia, obsessive compulsive behavior, attention deficit disorder, sleep disorders, irritability, impulsivity, anger management, multiple sclerosis and Parkinson's disease, inflammation, inflammatory bowel disease, sexual dysfunction, hypertension, retinal degeneration or an estrogen dependent cancer.

### Claim 9 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and another agent selected from: an organic bisphosphonate; a cathepsin K inhibitor; an estrogen; an estrogen receptor modulator; an androgen receptor modulator; an inhibitor of osteoclast proton ATPase; an inhibitor of HMG-CoA reductase; an integrin receptor antagonist; an osteoblast anabolic agent; calcitonin; Vitamin D; a synthetic Vitamin D analogue; a selective serotonin reuptake inhibitor; an aromatase inhibitor; or a pharmaceutically acceptable salt or mixture thereof.

### Claim 10 (depends on 8)

The use of claim 8 further comprising another agent selected from: an organic bisphosphonate; a cathepsin K inhibitor; an estrogen; an estrogen receptor modulator; an androgen receptor modulator; an inhibitor of osteoclast proton ATPase; an inhibitor of HMG-CoA reductase; an integrin receptor antagonist; an osteoblast anabolic agent; calcitonin; Vitamin D; a synthetic Vitamin D analogue; a selective serotonin reuptake inhibitor; an aromatase inhibitor; or a pharmaceutically acceptable salt or mixture thereof.
